UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K/A
Amendment
No. 1
|
(Mark
One)
|
|
|
x
|
ANNUAL REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
|
|
|
|
|
For the fiscal year ended
December 31, 2008
|
|
|
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For
the transition period from __________________ to
______________________.
Commission File Number:
333-145507
OMNIMMUNE
HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of incorporation)
|
26-3128407
(IRS
Employer Identification No.)
|
Omnimmune
Holdings, Inc.
4600
Post Oak Place, Suite 352
Houston, Texas
77027
(Address
of principal executive offices)
(713)
622-8400
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act: None
Securities
registered pursuant to section 12(g) of the Act: None.
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities Act.
r
Yes
x
No
Indicate
by check mark if the registrant is not required to file reports pursuant to
Section 13 or 15(d) of the Act.
r
Indicate
by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
x
Yes
r
No
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the best
of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K.
r
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
definition of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large
accelerated filer
r
|
Accelerated
filer
r
|
Non-accelerated
filer
r
(Do
not check if a smaller reporting company)
|
Smaller
reporting company
x
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Act).
r
Yes
x
No
The
estimated aggregate market value of the common stock held by non-affiliates of
the registrant (which includes all holders other than executive officers,
directors and holders of 10% or more of the outstanding common stock of the
registrant) as of June 30, 2008, the last business day of the registrant’s most
recently completed second fiscal quarter, was approximately $1,100,000 based on
the closing price of the stock as reported by the OTC Bulletin Board on June 30,
2008.
8,814,921
shares of our common stock were issued and outstanding as of April 6,
2009.
Documents
incorporated by reference: None.
PRELIMINARY
NOTE
This
Amendment No. 1 to Omnimmune Holdings Inc.’s Annual Report on Form 10-K for
the year ended December 31, 2008 amends only the items listed below. With
respect to each item, we are amending the annual report to delete the disclosure
under that item contained in our Annual Report on Form 10-K and to replace it in
its entirety with the disclosure contained in this amendment.
TABLE
OF CONTENTS
|
|
Page
|
|
|
|
PART
II
|
|
|
Item
9A.
|
|
1
|
|
|
|
SIGNATURES
|
|
2
|
|
|
|
CERTIFICATION
|
|
|
PART
II
Management’s Report on Disclosure
Controls and Procedures
Our
management is responsible for establishing and maintaining adequate internal
control over financial reporting, as such term is defined in Rule 13a-15(f) of
the Exchange Act. Because of its inherent limitations, internal control over
financial reporting is not intended to provide absolute assurance that a
misstatement of our financial statements would be prevented or
detected. As required by Exchange Act Rule 13a-15(f), as of the end
of the period covered by the Annual Report on Form 10-K for the year ended
December 31, 2008, our management, under the supervision and with the
participation of the Company's Chief Executive Officer and Chief Financial (and
principal accounting) Officer conducted an evaluation of the effectiveness of
our internal control over financial reporting with reference to the framework in
Internal Control--Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO).
Based on
that evaluation, our Chief Executive Officer and Chief Financial Officer (the
same person has both titles) concluded that as of December 31, 2008, due to the
material weakness existing in our internal controls, our disclosure controls and
procedures were ineffective.
Significant
Deficiencies in Disclosure Controls and Procedures or Internal
Controls
We have
determined there were disclosure errors in Item 9A - Internal Controls Over
Financial Reporting as contained in our Form 10-K for the year ended December
31, 2008, as filed with the SEC on April 15, 2009. This report did
not include all disclosures as required by Item 308T of Regulation
S-K.
The
Company is currently conducting a review in order to design enhanced controls
and procedures to remedy this deficiency. The Company is not aware of any other
deficiencies in its system of disclosure controls and procedures.
This
annual report does not include an audit report of our registered public
accounting firm regarding internal control over financial reporting. In
addition, management's report on internal control over financial reporting was
not subject to attestation by our registered public accounting firm pursuant to
temporary rules of the SEC that permit us to provide only management's report in
this annual report.
Changes
in Internal Control over Financial Reporting
Except as
described above, there were no changes in internal controls over financial
reporting that occurred during the period covered by this report that have
materially affected, or are reasonably likely to materially effect, our internal
control over financial reporting.
SIGNATURES
In
accordance with the Exchange Act, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly
authorized.
|
OMNIMMUNE
HOLDINGS, INC.
|
|
|
|
January
22, 2010
|
|
|
|
By:
|
/s/
Harris A.
Lichtenstein,
|
|
Name:
|
Harris
A. Lichtenstein, Ph.D.
|
|
Title:
|
President,
Chief Executive Officer and Director
|
|
|
(Principal
Executive, Financial, and Accounting
Officer)
|
In
accordance with the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the Registrant and in the capacities
and on the dates indicated.
January
22, 2010
|
By:
|
/s/
Harris A.
Lichtenstein,
|
|
Name:
|
Harris
A. Lichtenstein, Ph.D.
|
|
Title:
|
President,
Chief Executive Officer and Director
|
|
|
(Principal
Executive, Financial, and Accounting Officer)
|
|
|
|
January
22, 2010
|
By:
|
/s/
Mark
German
|
|
Name:
|
Mark
S. Germain
|
|
Title:
|
Chairman
of the Board of Directors
|
|
|
|
January
22, 2010
|
By:
|
|
|
Name:
|
Alexander
Krichevsky, D.V.M.
|
|
Title:
|
Director
|
|
|
|
January
22, 2010
|
By:
|
/s/
Charles
Duff
|
|
Name:
|
Charles
Duff
|
|
Title:
|
Director
|
|
|
|
January
22, 2010
|
By:
|
|
|
Name:
|
Matthew
A. Gonda, Ph.D.
|
|
Title:
|
Director
|